USA flag logo/image

An Official Website of the United States Government

CD4 Based Therapeutic Vaccine for HIV

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
29086
Program Year/Program:
1995 / SBIR
Agency Tracking Number:
29086
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
MEDIMMUNE, INC.
35 WEST WATKINS MILL RD Gaithersburg, MD 20878
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 1995
Title: CD4 Based Therapeutic Vaccine for HIV
Agency: HHS
Contract: 1 R43 AI36029-01A1,
Award Amount: $99,983.00
 

Abstract:

An effective therapeutic vaccine for HIV should be capable of reducing viral load and spread of infprevent the onset of AIDS. In an SIV-rhesus macaque model, immunization with a recombinant, solubleCD4 molecule (rsCD4) induced an anti-CD4 response that reduced viral load and rendered PBLs from theanimals resistant to infection with SIV. This anti-viral activity was found in the IgG fraction of tI clinical study HIV-infected individuals immunized with human rsCD4 in IFA developed an anti-CD4 reachieved were insufficient to prevent spread of HIV. These results suggest that B cell tolerance toovercome. This application will focus on developing strategies for enhancing immune responses to rsCmodel tolerant to human CD4. In particular, a series of vaccines composed of vaccines composed of rhprotein conjugates of CD4-derived peptide conjugates formulated in different adjuvants will be evaluenhance T helper and B cell responses in a mouse model expressing a human CD4 transgene. This studyselection of a more immunogenic rsCD4 formulation for clinical study.

Principal Investigator:

David Cassatt
30117

Business Contact:

Small Business Information at Submission:

Medimmune, Inc.
35 West Watkins Mill Road Gaithersburg, MD 20878

EIN/Tax ID:
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No